ClinicalTrials.gg
CompletedNCT04518306GMRx2_PCTUpdated Jun 3, 2025Results posted

Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

A Phase 3 interventional study of Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg and Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg in Hypertension, sponsored by George Medicines PTY Limited. Completed at 47 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by George Medicines PTY Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
755
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
18th of 99
755 · median 184
Started
2021
with 2 others
Phase 3
40 of 99
none open now
Registered
89th of 99
by date
Lead sponsor
2 of 99
George Medicines PTY Limited

Among the 99 studies testing telmisartan in Hypertension, this one is the 18th largest by enrollment, is one of 3 that started in 2021, is one of 40 in phase 3, and was the 89th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to placebo.

Read the detailed description

TRIAL DRUG:

GMRx2: single pill combination of telmisartan/amlodipine/indapamide Dose version 1: telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg Dose version 2: telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg INDICATION: Hypertension

TRIAL TITLE:

Efficacy and safety of GMRx2 compared to placebo for the treatment of hypertension.

OBJECTIVES:

To investigate the efficacy and safety of GMRx2 compared to placebo for the treatment of hypertension.

INTERVENTION:

A 2-week single-blind placebo run-in will be followed by a 4-week double-blind period with randomization to GMRx2 dose version 1, GMRx2 dose version 2 or placebo.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At screening visit:

  1. Provided signed consent to participate in the trial.
  2. Adult aged ≥18 years.
  3. Low calculated CV risk according to local guidelines such that pharmacological BP-lowering treatment is not mandatory: e.g. Pooled Cohorts Equation 10-years ASCVD risk \<10% in the USA.
  4. Likely diagnosis of hypertension, defined as one or more of:

    • automated SBP at this clinic visit according to trial methods (see Appendix 2) of ≥130mmHg on no BP lowering medicines or ≥120mmHg on 1 BP lowering medicine that will be stopped at this visit, OR
    • documentation in last 6 months of office SBP ≥ 140 mmHg and/or DBP ≥ 90mmHg on no BP lowering medicines or SBP ≥ 130 mmHg and/or DBP ≥ 85mmHg on 1 BP lowering medicine that will be stopped at this visit, OR
    • documentation in last 6 months of home SBP ≥ 130 mmHg and/or DBP ≥ 80mmHg on no BP lowering medicines or SBP ≥ 120 mmHg and/or DBP ≥ 75mmHg on 1 BP lowering medicine that will be stopped at this visit, OR
    • documentation in last 6 months of ambulatory daytime SBP ≥ 130 mmHg and/or DBP ≥ 80mmHg on no BP lowering medicines or SBP ≥ 120 mmHg and/or DBP ≥ 75mmHg on 1 BP lowering medicine that will be stopped at this visit
  5. No to trial medications, including 2-weeks placebo run-in and 4-weeks randomized treatment period with GMRx2 (dose version 1 or 2) or placebo.

At randomization visit:

  1. Home seated mean SBP 130-154 mmHg in the week before the randomization visit.
  2. Adherence of 80-120% to placebo run-in.
  3. Tolerated placebo run-in.
  4. Adherence to home BP monitoring schedule: in the week before randomization, at least 6 measures (e.g. ≥2 sets of triplicate measures) including at least 1 morning and 1 evening each with ≥2 measures. Morning is defined as any measure in the am and evening as any measure in the pm. Morning and evening do not have to be same day.

Exclusion criteria

Exclusion Criteria:

At screening visit:

  1. Receiving 2 or more BP-lowering drugs.
  2. Clinic seated mean SBP ≥160 mmHg and/or DBP ≥100 mmHg.
  3. Pregnant or had a positive pregnancy test or unwilling to undertake a pregnancy test during the trial and up to 30 days after the discontinuation of the trial medication or breastfeeding or of childbearing age and not using an acceptable method of . Acceptable methods of birth control include hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (e.g. condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), or male partner sterilization. Contraception should be used for at least 1 month before the screening visit and until the end of trial participation.
  4. Not suitable for participation in a clinical trial according to local ethical or regulatory requirements related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
  5. , including (e.g. anaphylaxis or angioedema), to any of the 3 trial medications.
  6. Current/history of , stroke, or hypertensive encephalopathy.
  7. Current/history of acute coronary syndrome, unstable angina, myocardial infarction, percutaneous transluminal coronary revascularization, or coronary artery bypass graft.
  8. Current/history of class III and IV congestive heart failure.
  9. Current/history of a known secondary cause of hypertension, such as primary aldosteronism, renal artery stenosis, pheochromocytoma, or Cushing's syndrome.
  10. Current/history of substantially uncontrolled diabetes ( > 11.0%) within last three months.
  11. Current/history of end-stage renal disease or anuria or estimated (eGFR) \<60 ml/min/1.73m2.
  12. Current/history of (AST) or alanine aminotransferase (ALT) >3 times the within 6 months.
  13. Current concomitant illness or physical impairment or mental condition that in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
  14. Arm circumference that is too large (>55 cm) or too small (\<20 cm) to allow accurate measurement of BP.
  15. Currently taking or might need during the trial, a concomitant treatment which is known to interact significantly with the trial medication: digoxin, lithium, diabetics receiving aliskiren, moderate and strong inhibitors [e.g. ritonavir, ketoconazole, diltiazem], simvastatin >20 mg/day, .
  16. Might need treatment with drugs that are prohibited during the trial: other antihypertensive drugs, endothelin receptor antagonists, neprilysin inhibitors, or other drugs that may affect BP (see Error! Reference source not found.).
  17. Current surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of trial drugs such as prior major gastrointestinal tract surgery (e.g. gastrectomy, lap band, or bowel resection) or acute flare of inflammatory bowel disease within one year.
  18. Individuals working >2-night shifts per week.
  19. Participated in any drug or device trial within the previous 30 days.
  20. History of alcohol or drug abuse within 12 months.

At randomization visit:

  1. Unable to adhere to the trial procedures during the run-in period.
  2. Any of the following which in the investigator's judgment may compromise the safety of the participant if randomized to the trial medications:

    1. High or low clinic BP levels even in the light of the values for home BP that are available for that participant. The exact levels of BP are not specified, since there is clinical uncertainty as to the relevance of BP levels which are high/low in clinic only; for example the clinical relevance of 'whitecoat hypertension' is uncertain.
    2. High or low home DBP levels. The exact levels of DBP are not specified, reflecting clinical uncertainty of for example isolated diastolic hypertension. However, home DBP values of >99 mmHg may typically be considered as requiring treatment intensification, and such participants would not be suitable for randomization.
  3. Any abnormal laboratory value which in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
  4. Fulfilling any of the exclusion criteria mentioned for the screening visit, when verified again at randomization visit.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
755 participants (actual)

Study arms

  • Experimental
    Triple ¼ (GMRx2)

    Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg

    Drug: Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg

  • Active comparator
    Triple ½ (GMRx2)

    Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg

    Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugTelmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg

    Drug page: Telmisartan

    Oral tablets

  • DrugTelmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg

    Drug page: Telmisartan

    Oral tablets

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4

    Each blood pressure (BP) measurement consisted of valid SBP values (ie. SBP\>60 mmHg and \<250 mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.

    Time frame: Randomization to Week 4

Secondary outcomes

  1. Difference in Change in Clinic Seated Mean Mean Systolic Blood Pressure (SBP) From Randomization to Week 4

    Each blood pressure (BP) measurement consisted of valid SBP values (ie. SBP\>60 mmHg and \<250 mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.

    Time frame: Randomization to Week 4

  2. Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4

    Each blood pressure (BP) measurement consisted of valid DBP values (ie. DBP\>40mmHg and \<150mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.

    Time frame: Randomization to Week 4

  3. Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and DBP <90 mmHg at Week 4

    The percentage of participants achieving averaged clinic SBP \<140 and DBP \<90 mmHg at Week 4 was evaluated.

    Time frame: At Week 4

  4. Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4

    The percentage of participants achieving averaged clinic SBP \<130 and DBP \<80 mmHg at Week 4 was evaluated. Participants were analyzed in the treatment group to which they have been randomized.

    Time frame: At Week 4

  5. Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4

    Each blood pressure (BP) measurement consisted of valid DBP values (ie. DBP\>40mmHg and \<150mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups. To evaluate the difference in change, least squares mean change value is reported.

    Time frame: Randomization to Week 4

  6. Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4

    Difference in change in trough home SBP for GMRx2 vs placebo was evaluated at Week 4. Trough values were measured before morning dose of the study medication.

    Time frame: Randomization to Week 4

  7. Difference in Change in Trough Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4

    Difference in change in trough home DBP for GMRx2 vs placebo was evaluated at Week 4. Trough values were measured before morning dose of the study medication. To evaluate the difference in change, least squares mean change value is reported.

    Time frame: Randomization to Week 4

  8. Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 4

    The percentage of participants achieving home seated mean SBP \<135 and DBP \<85 mmHg at Week 4 was evaluated

    Time frame: At Week 4

  9. Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4

    The percentage of participants achieving averaged home seated mean SBP \<130 and DBP \<80 mmHg at Week 4 was evaluated

    Time frame: Randomization to Week 4

Other outcomes

  1. Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE) or a Serious Adverse Event (SAE) From Randomization to Week 4

    The primary safety outcome is percentage of participants discontinued trial medication due to an Adverse Event (AE) or a Serious Adverse Event (SAE) from randomization to Week 4.

    Time frame: Randomization to Week 4

  2. Percentage of Participants With an Serious Adverse Event (SAE) From Randomization to Week 4

    The secondary outcome is percentage of participants with an SAE from randomization to Week 4

    Time frame: Randomization to Week 4

  3. Percentage of Participants With Symptomatic Hypotension From Randomization to Week 4

    The Secondary Safety Outcome is percentage of participants with symptomatic hypotension from randomization to Week 4

    Time frame: Randomization to Week 4

  4. Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 4

    The Secondary safety outcome is percentage of participants with serum sodium concentration below 135 mmol/l at Week 4

    Time frame: At Week 4

  5. Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 4

    The Secondary safety outcome is percentage of participants with serum sodium concentration above 145 mmol/l at Week 4

    Time frame: At Week 4

  6. The Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 4

    The secondary safety outcome is percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 4

    Time frame: At Week 4

  7. Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 4

    The secondary safety outcome is percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 4.

    Time frame: At Week 4

  8. Percentage of Participants With eGFR Drop of Over 30% From Randomization to Week 4

    The secondary safety outcome is percentage of participants with eGFR drop of over 30% from randomization to Week 4

    Time frame: Randomization to Week 4

  9. Percentage of Participants With Serum Sodium <135mmol/l or >145 mmol/l, and/or Serum Potassium <3.5 mmol/l or >5.5mmol/l at Week 4

    The secondary safety outcome is percentage of participants with serum sodium \<135mmol/l or \>145 mmol/l, and/or serum potassium \<3.5 mmol/l or \>5.5mmol/l at Week 4

    Time frame: At Week 4

  10. Percentage of Participants With Postural Hypotension at Week 4

    The secondary safety outcome percentage of participants with postural hypotension at Week 4

    Time frame: At Week 4

  11. Percentage of Participants With Postural Hypertension at Week 4

    The secondary safety outcome is percentage of participants with postural hypertension at Week 4

    Time frame: At Week 4

07

Results

Posted Jun 3, 2025

Participant flow

The trial was conducted at 47 trial centers spread across 5 countries (United States of America \[USA\] 23, Great Britain 10, Sri Lanka 7, Australia 5, and Nigeria 2).

Single-Blind Placebo Run-In Period
Participant flow — Single-Blind Placebo Run-In Period
MilestoneTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Started00755
Completed00295
Not completed00460
Double-Blind Period
Participant flow — Double-Blind Period
MilestoneTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Started11311963
Completed919150
Not completed222813
Withdrew: Run in failure001
Withdrew: Adverse event022
Withdrew: Lost to follow-up122
Withdrew: Participant moved to open-label extension (ole) study21218
Withdrew: Other020
Withdrew: Missing010

Outcome measures

PrimaryDifference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4

Each blood pressure (BP) measurement consisted of valid SBP values (ie. SBP\>60 mmHg and \<250 mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.

Time frame:
Randomization to Week 4
Reported as:
Least squares mean · mmHg
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4
mmHgTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4-9.6 ± 1.00-10.4 ± 1.33-2.2 ± 1.16
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · MIANALYZE procedure · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -7.33 · 95% CI -10.176 to -4.486
  • Triple ½ (GMRx2) vs Placebo · MIANALYZE procedure · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -8.23 · 95% CI -11.305 to -5.151
SecondaryDifference in Change in Clinic Seated Mean Mean Systolic Blood Pressure (SBP) From Randomization to Week 4

Each blood pressure (BP) measurement consisted of valid SBP values (ie. SBP\>60 mmHg and \<250 mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.

Time frame:
Randomization to Week 4
Reported as:
Least squares mean · mmHg
Difference in Change in Clinic Seated Mean Mean Systolic Blood Pressure (SBP) From Randomization to Week 4
mmHgTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Difference in Change in Clinic Seated Mean Mean Systolic Blood Pressure (SBP) From Randomization to Week 4-6.6 ± 0.94-8.2 ± 1.251.3 ± 1.19
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · MMRM procedure · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -7.98 · 95% CI -11.281 to -4.681
  • Triple ½ (GMRx2) vs Placebo · MMRM procedure · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -9.52 · 95% CI -13.588 to 5.449
SecondaryDifference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4

Each blood pressure (BP) measurement consisted of valid DBP values (ie. DBP\>40mmHg and \<150mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.

Time frame:
Randomization to Week 4
Reported as:
Least squares mean · mmHg
Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4
mmHgTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4-3.5 ± 0.60-4.3 ± 0.930.5 ± 0.91
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · MMRM procedure · p = 0.0015 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -4.00 · 95% CI -6.413 to -1.597
  • Triple ½ (GMRx2) vs Placebo · MMRM procedure · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -4.86 · 95% CI -7.130 to -2.595
SecondaryPercentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and DBP <90 mmHg at Week 4

The percentage of participants achieving averaged clinic SBP \<140 and DBP \<90 mmHg at Week 4 was evaluated.

Time frame:
At Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and DBP <90 mmHg at Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and DBP <90 mmHg at Week 4738323
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Wald test · p = 0.0002 · Risk difference (rd): 28.09 · 95% CI 11.811 to 42.45095% confidence intervals for risk difference utilized Newcombe estimation method
  • Triple ½ (GMRx2) vs Placebo · Wald test · p = <0.0001 · Risk difference (rd): 33.24 · 95% CI 17.199 to 47.18695% confidence intervals for risk difference utilize Newcombe estimation method
SecondaryPercentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4

The percentage of participants achieving averaged clinic SBP \<130 and DBP \<80 mmHg at Week 4 was evaluated. Participants were analyzed in the treatment group to which they have been randomized.

Time frame:
At Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 423362
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Wald test · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo.) · Risk difference (rd): 17.18 · 95% CI 6.070 to 26.38595% confidence intervals for risk difference utilized Newcombe estimation method.
  • Triple ½ (GMRx2) vs Placebo · Wald test · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Risk difference (rd): 27.08 · 95% CI 15.237 to 36.64695% confidence intervals for risk difference utilized Newcombe estimation method
SecondaryDifference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4

Each blood pressure (BP) measurement consisted of valid DBP values (ie. DBP\>40mmHg and \<150mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups. To evaluate the difference in change, least squares mean change value is reported.

Time frame:
Randomization to Week 4
Reported as:
Least squares mean · mmHg
Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4
mmHgTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4-5.1 ± 0.76-6.6 ± 0.60-1.1 ± 0.79
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · MMRM procedure · p = 0.0002 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -4.00 · 95% CI -5.978 to -2.013
  • Triple ½ (GMRx2) vs Placebo · MMRM procedure · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -5.51 · 95% CI -7.328 to -3.694
SecondaryDifference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4

Difference in change in trough home SBP for GMRx2 vs placebo was evaluated at Week 4. Trough values were measured before morning dose of the study medication.

Time frame:
Randomization to Week 4
Reported as:
Least squares mean · mmHg
Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4
mmHgTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4-8.1 ± 1.24-10.1 ± 1.36-1.3 ± 1.24
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · MMRM procedure · p = 0.0003 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -6.79 · 95% CI -10.300 to -3.287
  • Triple ½ (GMRx2) vs Placebo · MMRM procedure · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -8.74 · 95% CI -12.403 to -5.082
SecondaryDifference in Change in Trough Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4

Difference in change in trough home DBP for GMRx2 vs placebo was evaluated at Week 4. Trough values were measured before morning dose of the study medication. To evaluate the difference in change, least squares mean change value is reported.

Time frame:
Randomization to Week 4
Reported as:
Least squares mean · mmHg
Difference in Change in Trough Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4
mmHgTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Difference in Change in Trough Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4-4.2 ± 0.83-5.7 ± 0.65-0.3 ± 0.93
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · MMRM procedure · p = 0.0003 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -3.86 · 95% CI -5.865 to -1.847
  • Triple ½ (GMRx2) vs Placebo · MMRM procedure · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Ls means difference: -5.42 · 95% CI -7.915 to -2.932
SecondaryPercentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 4

The percentage of participants achieving home seated mean SBP \<135 and DBP \<85 mmHg at Week 4 was evaluated

Time frame:
At Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 4676415
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Wald test · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Risk difference (rd): 35.48 · 95% CI 19.541 to 48.54995% confidence intervals for risk difference utilized Newcombe estimation method
  • Triple ½ (GMRx2) vs Placebo · Wald test · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Risk difference (rd): 29.97 · 95% CI 14.218 to 43.09395% confidence intervals for risk difference utilized Newcombe estimation method
SecondaryPercentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4

The percentage of participants achieving averaged home seated mean SBP \<130 and DBP \<80 mmHg at Week 4 was evaluated

Time frame:
Randomization to Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 432407
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Wald test · p = 0.0030 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Risk difference (rd): 17.21 · 95% CI 3.637 to 28.42495% confidence intervals for risk difference utilized Newcombe estimation method
  • Triple ½ (GMRx2) vs Placebo · Wald test · p = <0.0001 (No adjustment for multiplicity was made and the 0.05 level of significance was used to claim efficacy compared with placebo) · Risk difference (rd): 22.50 · 95% CI 8.720 to 33.66595% confidence intervals for risk difference utilized Newcombe estimation method
Other pre-specifiedPercentage of Participants Discontinued Trial Medication Due to Adverse Event (AE) or a Serious Adverse Event (SAE) From Randomization to Week 4

The primary safety outcome is percentage of participants discontinued trial medication due to an Adverse Event (AE) or a Serious Adverse Event (SAE) from randomization to Week 4.

Time frame:
Randomization to Week 4
Reported as:
Count of participants · Participants
Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE) or a Serious Adverse Event (SAE) From Randomization to Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE) or a Serious Adverse Event (SAE) From Randomization to Week 4061
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Risk difference (rd): -1.61 · 95% CI -9.830 to 2.76095% confidence intervals for risk difference utilized Newcombe estimation method
  • Triple ½ (GMRx2) vs Placebo · Risk difference (rd): 3.47 · 95% CI -5.276 to 9.77495% confidence intervals for risk difference utilized Newcombe estimation method
Other pre-specifiedPercentage of Participants With an Serious Adverse Event (SAE) From Randomization to Week 4

The secondary outcome is percentage of participants with an SAE from randomization to Week 4

Time frame:
Randomization to Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With an Serious Adverse Event (SAE) From Randomization to Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With an Serious Adverse Event (SAE) From Randomization to Week 4022
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Risk difference (rd): -3.23 · 95% CI -12.171 to 1.66295% confidence intervals for risk difference utilized Newcombe estimation method
  • Triple ½ (GMRx2) vs Placebo · Risk difference (rd): -1.53 · 95% CI -10.585 to 4.049
Other pre-specifiedPercentage of Participants With Symptomatic Hypotension From Randomization to Week 4

The Secondary Safety Outcome is percentage of participants with symptomatic hypotension from randomization to Week 4

Time frame:
Randomization to Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With Symptomatic Hypotension From Randomization to Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With Symptomatic Hypotension From Randomization to Week 4460
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Risk difference (rd): 3.54 · 95% CI -4.115 to 9.35295% confidence intervals for risk difference utilize Newcombe estimation method
  • Triple ½ (GMRx2) vs Placebo · Risk difference (rd): 5.08 · 95% CI -2.779 to 11.200
Other pre-specifiedPercentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 4

The Secondary safety outcome is percentage of participants with serum sodium concentration below 135 mmol/l at Week 4

Time frame:
At Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 4410
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Risk difference (rd): 3.54 · 95% CI -4.012 to 9.35095% confidence intervals for risk difference utilized Newcombe estimation method
  • Triple ½ (GMRx2) vs Placebo · Risk difference (rd): 0.84 · 95% CI -6.364 to 5.27895% confidence intervals for risk difference utilized Newcombe estimation method
Other pre-specifiedPercentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 4

The Secondary safety outcome is percentage of participants with serum sodium concentration above 145 mmol/l at Week 4

Time frame:
At Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 4453
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Risk difference (rd): -1.22 · 95% CI -10.928 to 5.57395% confidence intervals for risk difference utilize Newcombe estimation method
  • Triple ½ (GMRx2) vs Placebo · Risk difference (rd): 4.27 · 95% CI 1.38 to 9.5395% confidence intervals for risk difference utilize Newcombe estimation method
Other pre-specifiedThe Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 4

The secondary safety outcome is percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 4

Time frame:
At Week 4
Reported as:
Count of participants · Participants
The Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
The Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 4461
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Risk difference (rd): 1.95 · 95% CI -6.492 to 7.95495% confidence intervals for risk difference utilized Newcombe estimation method
  • Triple ½ (GMRx2) vs Placebo · Risk difference (rd): 3.45 · 95% CI -5.171 to 9.70495% confidence intervals for risk difference utilized Newcombe estimation method
Other pre-specifiedPercentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 4

The secondary safety outcome is percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 4.

Time frame:
At Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 4100
Statistical analysis
  • Triple ¼ (GMRx2) · Risk difference (rd): 0.88 · 95% CI -6.324 to 5.54895% confidence intervals for risk difference utilized Newcombe estimation method
  • Triple ½ (GMRx2) vs Placebo · Number of participants at 95% ci: 0 · 95% CI 0.00 to 3.05For this particular parameter we have used number of participants at 95% CI computed from Clopper-Pearson method as no risk difference was found between the Triple ½ (GMRx2) vs placebo
Other pre-specifiedPercentage of Participants With eGFR Drop of Over 30% From Randomization to Week 4

The secondary safety outcome is percentage of participants with eGFR drop of over 30% from randomization to Week 4

Time frame:
Randomization to Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With eGFR Drop of Over 30% From Randomization to Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With eGFR Drop of Over 30% From Randomization to Week 4001
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Risk difference (rd): -1.59 · 95% CI -9.684 to 2.77895% confidence intervals for risk difference utilized Newcombe estimation method
  • Triple ½ (GMRx2) vs Placebo · Risk difference (rd): -1.59 · 95% CI -9.684 to 2.59095% confidence intervals for risk difference utilized Newcombe estimation method.
Other pre-specifiedPercentage of Participants With Serum Sodium <135mmol/l or >145 mmol/l, and/or Serum Potassium <3.5 mmol/l or >5.5mmol/l at Week 4

The secondary safety outcome is percentage of participants with serum sodium \<135mmol/l or \>145 mmol/l, and/or serum potassium \<3.5 mmol/l or \>5.5mmol/l at Week 4

Time frame:
At Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With Serum Sodium <135mmol/l or >145 mmol/l, and/or Serum Potassium <3.5 mmol/l or >5.5mmol/l at Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With Serum Sodium <135mmol/l or >145 mmol/l, and/or Serum Potassium <3.5 mmol/l or >5.5mmol/l at Week 412124
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Risk difference (rd): 4.27 · 95% CI -6.722 to 12.95995% confidence intervals for risk difference utilized Newcombe estimation method.
  • Triple ½ (GMRx2) vs Placebo · Risk difference (rd): 3.73 · 95% CI -7.158 to 12.13395% confidence intervals for risk difference utilized Newcombe estimation method.
Other pre-specifiedPercentage of Participants With Postural Hypotension at Week 4

The secondary safety outcome percentage of participants with postural hypotension at Week 4

Time frame:
At Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With Postural Hypotension at Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With Postural Hypotension at Week 4743
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · Risk difference (rd): 1.43 · 95% CI -8.585 to 8.916
  • Triple ½ (GMRx2) vs Placebo · Risk difference (rd): -1.40 · 95% CI -11.077 to 5.161
Other pre-specifiedPercentage of Participants With Postural Hypertension at Week 4

The secondary safety outcome is percentage of participants with postural hypertension at Week 4

Time frame:
At Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With Postural Hypertension at Week 4
ParticipantsTriple ¼ (GMRx2)Triple ½ (GMRx2)Placebo
Percentage of Participants With Postural Hypertension at Week 4193113
Statistical analysis
  • Triple ¼ (GMRx2) vs Placebo · GEE procedure · p = <0.0001 · Risk difference (rd): -3.82 · 95% CI -17.664 to 8.366
  • Triple ½ (GMRx2) vs Placebo · GEE procedure · p = <0.0001 · Ls means: 5.42 · 95% CI -9.040 to 17.981

Adverse events

Collected over 6 weeks (Single-blind placebo run-in period of 2 weeks and double-blind period of 4 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triple ¼ (GMRx2)0/113 (0%)0/113 (0%)25/113 (22.1%)
Triple ½ (GMRx2)0/119 (0%)3/119 (2.5%)32/119 (26.9%)
Placebo0/63 (0%)2/63 (3.2%)10/63 (15.9%)
Not Randomized0/460 (0%)2/460 (0.4%)17/460 (3.7%)
Most frequent serious events
Most frequent serious events
EventTriple ¼ (GMRx2)Triple ½ (GMRx2)PlaceboNot Randomized
COVID-19Infections and infestations0/1132/1192/630/460
Cerebrovascular accidentNervous system disorders0/1131/1190/630/460
ArteritisVascular disorders0/1130/1190/631/460
HypertensionVascular disorders0/1130/1190/631/460
Most frequent other events
Showing 10 of 52
Most frequent other events
EventTriple ¼ (GMRx2)Triple ½ (GMRx2)PlaceboNot Randomized
HeadacheNervous system disorders5/1132/1195/632/460
Blood uric acid increasedInvestigations2/1135/1191/630/460
DizzinessNervous system disorders0/1133/1190/632/460
DyslipidaemiaMetabolism and nutrition disorders2/1130/1190/630/460
Blood potassium decreasedInvestigations2/1130/1191/630/460
Blood sodium increasedInvestigations0/1132/1191/630/460
HypokalaemiaMetabolism and nutrition disorders0/1132/1190/630/460
Blood cholesterol increasedInvestigations0/1132/1191/630/460
Blood glucose increasedInvestigations0/1132/1190/630/460
Glomerular filtration rate decreasedInvestigations0/1132/1190/630/460

Baseline characteristics

Baseline characteristics were summarized on the safety population by randomized treatment groups

Age, Continuous
Age, Continuous(years)Triple ¼ (GMRx2)Triple ½ (GMRx2)PlaceboTotal
Mean49.5 ± 12.2551.2 ± 9.8850.9 ± 12.8150.5 ± 11.47
Sex: Female, Male
Sex: Female, Male(Participants)Triple ¼ (GMRx2)Triple ½ (GMRx2)PlaceboTotal
Female686136165
Male455827130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Triple ¼ (GMRx2)Triple ½ (GMRx2)PlaceboTotal
Hispanic or Latino404223105
Not Hispanic or Latino707638184
Unknown or Not Reported3126
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Triple ¼ (GMRx2)Triple ½ (GMRx2)PlaceboTotal
American Indian or Alaska Native2013
Asian2627861
Native Hawaiian or Other Pacific Islander1001
Black or African American18201149
White667243181
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Triple ¼ (GMRx2)Triple ½ (GMRx2)PlaceboTotal
United States596533157
Sri Lanka1918643
United Kingdom18151043
Australia15161142
Nigeria25310
Height
Height(cm)Triple ¼ (GMRx2)Triple ½ (GMRx2)PlaceboTotal
Mean165.97 ± 10.439166.68 ± 10.247167.36 ± 9.878166.55 ± 10.223
Weight
Weight(kg)Triple ¼ (GMRx2)Triple ½ (GMRx2)PlaceboTotal
Mean85.50 ± 20.86585.12 ± 22.41984.92 ± 20.29985.22 ± 21.319
BMI
BMI(kg/m^2)Triple ¼ (GMRx2)Triple ½ (GMRx2)PlaceboTotal
Mean30.9 ± 6.0430.4 ± 6.6930.0 ± 5.6730.5 ± 6.22

11 further baseline measures are reported on the registry.

08

Study locations

47 sites
  • Elite Clinical Studies
    Phoenix, Arizona 85018, United States
  • Headlands Research
    Scottsdale, Arizona 85260, United States
  • Quality of Life Medical & Research Centers, LLC
    Tucson, Arizona 85712, United States
  • Valiance Clinical Research
    S. Gate, California 90280, United States
  • Valiance Clinical Research
    Tarzana, California 91356, United States
  • Clinical Research of Brandon
    Brandon, Florida 33511, United States
  • Inpatient Research Clinic
    Hialeah, Florida 33013, United States
  • Suncoast Research Group
    Miami, Florida 33135, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Ocala Research Institute
    Ocala, Florida 34471, United States
  • Altus Research, Inc
    Palm Beach, Florida 33461, United States
  • Suncoast Research Associates
    Saint Petersburg, Florida 33173, United States
  • Accel Research
    Saint Petersburg, Florida 33709, United States
  • Precision Clinical Research
    Sunrise, Florida 33351, United States
  • Precision Research Center
    Tampa, Florida 33603, United States
  • Buckhead Primary Care Research
    Snellville, Georgia 30078, United States
  • Meridian Clinical Research
    Baton Rouge, Louisiana 70809, United States
  • The University of Tennessee Health Science Center
    Memphis, Tennessee 38105, United States
  • Synergy Groups Medical
    Houston, Texas 77036, United States
  • Synergy Groups Medical
    Houston, Texas 77087, United States
  • Synergy Groups Medical
    Missouri City, Texas 77459, United States
  • North Hills Medical Research
    North Richland Hills, Texas 76180, United States
  • Meridian Clinical Research
    Portsmouth, Virginia 23703, United States
  • Castle Hill Medical Centre
    Castle Hill, New South Wales 2154, Australia
  • Hudson Institute of Medical Research
    Clayton, Victoria 3168, Australia
  • Barwon Health, Geelong University Hospital
    Geelong, Victoria 3220, Australia
  • Curtin University
    Bentley, Western Australia 6102, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • University of Abuja Teaching Hospital
    Gwagwalada, Federal Capital Territory 902101, Nigeria
  • Aminu Kano Teaching Hospital
    Kano, Nigeria
  • Institute of Cardiology, National Hospital of Sri Lanka
    Colombo, 10-01000, Sri Lanka
  • Colombo South Teaching Hospital
    Dehiwala, 10350, Sri Lanka
  • Karapitiya Teaching Hospital
    Galle, 80000, Sri Lanka
  • Jafna Teaching Hospital
    Jaffna, 40000, Sri Lanka
  • Kandy National Hospital
    Kandy, 20000, Sri Lanka
  • Kurunegala Teaching Hospital
    Kurunegala, 60000, Sri Lanka
  • Colombo North Teaching Hospital
    Ragama, 11010, Sri Lanka
  • Steploe Medical Centre
    Soham, Cambridgeshire CB7 5JD, United Kingdom
  • Newquay Medical
    Newquay, Cornwall TR7 1RU, United Kingdom
  • Burbage Surgery
    Hinckley, Leicestershire LE10 2SE, United Kingdom
  • Belmont Health Centre
    Harrow, London HA3 7LT, United Kingdom
  • West Walk Surgery
    Bristol, Somerset BS37 4AX, United Kingdom
  • Brockwood Medical Practice
    Betchworth, Surrey RH3 7NJ, United Kingdom
  • Lakeside Surgery
    Coventry, West Midlands CV3 6NF, United Kingdom
  • Trowbridge Health Centre
    Trowbridge, Wiltshire BA14 8LW, United Kingdom
  • Abbeywell Surgery
    Romsey, SO51 8EN, United Kingdom
  • Albany House Medical Centre
    Wellingborough, NN8 4RW, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No If the sponsor receives a request for study data, then such requests will be reviewed by sponsor following completion of regulatory submissions and review, and with support from members of the GMRX2 steering committee who will advise on the scientific merit and integrity of the proposed analysis.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Sep 2023, 27 months.

Results were first posted in Jun 2025, 1 year 8 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 27 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2020
First posted
Aug 19, 2020
StartActual
Jun 14, 2021
Primary completionActual
Sep 19, 2023
CompletionActual
Oct 18, 2023
Results first posted
Jun 3, 2025
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04518306
Lead sponsor
George Medicines PTY Limited
Responsible party
Sponsor
First posted
Aug 19, 2020
Start date
Jun 14, 2021
Primary completion
Sep 19, 2023
Completion
Oct 18, 2023
Results posted
Jun 3, 2025
Last update
Jun 3, 2025

Study contacts

Anthony Rodgers, Professor
principal investigator · The George Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion